Compare Nasdaq Inc (NDAQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Smith & Nephew plc — how do they compare? Nasdaq Inc trades at $95.99 (market cap $53.11B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Nasdaq Inc is far larger — about 4.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| NDAQ | SNN | |
|---|---|---|
Market Cap | $53.11B | $12.54B |
Sector | Financials | Health |
52-Week High | $100.98 | $38.70 |
52-Week Low | $76.85 | $28.73 |
Enterprise Value | $59.57B | $15.57B |
Dividend Yield | 1.22% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.92, up 0.31% on the day, with a bullish technical signal from moving averages and strong support at $95. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding expectations, and revenue growth accelerated to $8.26 billion in 2025. Recent news includes the acquisition of LeveL Markets, advancing its always-on markets strategy.
The outlook is positive, supported by analyst consensus of $109.20 price target and 61% buy ratings. Key opportunities include sustained revenue growth and strategic acquisitions, while risks involve competitive pressures and market volatility. The stock offers a dividend yield with recent payouts of $0.31 per share.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
